Vascular mechanisms: nitric oxide and angiogenesis
Of all the mechanisms attributed to BPC-157, two are developed enough to teach in detail, and both are about blood…
The two vascular stories BPC-157 tells best
Of all the mechanisms attributed to BPC-157, two are developed enough to teach in detail, and both are about blood vessels. The first is an unusual claim about the nitric oxide (NO) system: the originating group describes the peptide as competing with both an NO-synthase inhibitor and NO's own substrate, which is a relationship to the system rather than a defined action on it. The second is a receptor-level angiogenesis story centered on VEGFR2.
This unit takes both seriously and keeps both honest. The work is almost entirely rat and cell-culture, much of it single-lineage, and the same review that proposes the NO relationship closes by admitting that how it might translate into clinical performance remains to be determined.
Key terms
From injury to new vessel: the cascade
It helps to lay BPC-157’s vascular findings out as one ordered sequence rather than a list of separate tricks. In injured or ischaemic tissue, BPC-157 is reported to modulate the NO system and to raise VEGFR2 expression, which activates a VEGFR2-Akt-eNOS axis in the endothelium, which in turn supports new vessel formation and better-perfused healing tissue. Be clear about the status of that ordering: it is this course's arrangement of separate results, not a sequence any single study measured end to end.
Read left to right, this is the spine of the next four pages. Each box is a real reported finding, but the arrows are a model, not a proven chain in humans. Everything here comes from rat injury models and endothelial cell culture, so treat the cascade as a coherent hypothesis the data is consistent with, not as a verified human pathway.
AdvancedWhere this cascade comes from, and what it is not
Each box is a real reported finding, but they come from different papers, different preparations and different species: a rat hind-limb ischaemia study and human endothelial cell culture for the VEGFR2 and Akt-eNOS steps, isolated rat aorta rings for the NO step, muscle and tendon histology in treated animals for the vessel step. No study runs the whole chain, and FDA states that BPC-157's molecular targets have not been identified at all. Treat the arrows as this course's reading of how the pieces might fit, not as a demonstrated pathway.